drugset / Trial / NCT06294561
TGRX-326 Pharmacokinetic Drug Interaction
Phase 1
Completed
34 enrolled
Shenzhen TargetRx Co., Ltd.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer.
Timeline
- Start
- 2024-03-04
- Primary completion
- 2024-05-06
- Completion
- 2024-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | TGRX-326 | Unknown | 60 mg | Oral |